FDA approves Praxbind (idarucizumab) for reversal of the anticoagulant effects of dabigatran- Boehringer Ingelheim
The FDA has granted approval of Praxbind (idarucizumab), from Boehringer Ingelheim, indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. This indication is approved under accelerated approval based on a reduction in unbound dabigatran and normalisation of coagulation parameters in healthy volunteers. Continued approval for this indication may be contingent upon the results of an ongoing cohort case series study.
Praxbind was granted Breakthrough Therapy designation, the application received Priority Review and it was approved under an Accelerated Approval Pathway. The application included data from healthy volunteers as well as results from an interim analysis of the RE-VERSE AD trial (NCT02104947). In the studies, the reversal effects of idarucizumab were evident immediately, within minutes after administration of 5 grams of idarucizumab. No procoagulant effect was observed after the administration of idarucizumab. There are serious risks to consider when treating patients with idarucizumab, including warnings and precautions for thromboembolic risk, re-elevation of coagulation parameters, hypersensitivity reactions and risks of serious adverse reactions in patients with hereditary fructose intolerance due to sorbitol excipient. The most frequently reported adverse reactions (at least 5%) in idarucizumab-treated healthy volunteers was headache, and in the Phase III RE-VERSE AD study were hypokalaemia, delirium, constipation, pyrexia and pneumonia.
Comment: RE-VERSE AD, a global study investigating idarucizumab in actual clinical settings, is the only trial to examine patients being treated with dabigatran who are in need of emergency intervention or experience an uncontrolled or life-threatening bleeding event. Boehringer Ingelheim has had to settle 4,000 lawsuits in the US filed over claims about the extent of bleeding risks associated with dabigatran. The company has consistently backed the drug's positive benefit-risk profile, when used as directed, as has the FDA.
Related news and insights
MaaT Pharma reported that the FDA has responded to the Company’s Investigational New Drug (IND) Application to initiate in the U.S. an open-label, single arm Phase III pivotal clinical trial evaluating the safety and efficacy of MaaT 013 in patients with steroid-resistant acute Graft-versus-Host Disease (aGvHD).
Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III NRG-GY018 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS) for the treatment of patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status.
Gilead Sciences, Inc. has announced the FDA has approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.